Literature DB >> 27932677

Suite of clinically relevant functional assays to address therapeutic efficacy and disease mechanism in the dystrophic mdx mouse.

Yafeng Song1, Shira T Rosenblum1, Leon Morales1, Mihail Petrov1, Christopher Greer1, Samantha Globerman1, Hansell H Stedman2,3.   

Abstract

Duchenne muscular dystrophy (DMD) is a progressive primary myodegenerative disease caused by a genetic deficiency of the 427-kDa cytoskeletal protein dystrophin. Despite its single-gene etiology, DMD's complex pathogenesis remains poorly understood, complicating the extrapolation from results of preclinical studies in genetic homologs to the design of informative clinical trials. Here we describe novel phenotypic assays which when applied to the mdx mouse resemble recently used primary end points for DMD clinical trials. By coupling force transduction, high-precision motion tracking, and respiratory measurements, we have achieved a suite of integrative physiological tests that provide novel insights regarding normal and pathological responses to muscular exertion. A common feature of these physiological assays is the precise tracking and analysis of volitional movement, thereby optimizing the relevance to clinical tests. Unexpectedly, the measurable biological distinction between dystrophic and control mice at early time points in the disease process is better resolved with these tests than with the majority of previously used, labor-intensive studies of individual muscle function performed ex vivo. For example, the dramatic loss of volitional movement following a novel, standardized grip test distinguishes control mice from mdx mice by a 17.4-fold difference of the means (3.5 ± 2.2 vs. 60.9 ± 12.1 units of activity, respectively; effect size 1.99). The findings have both mechanistic and translational implications of potential significance to the fields of basic myology and neuromuscular therapeutics.NEW & NOTEWORTHY This study uses novel phenotypic assays which when applied to the mdx mouse resemble recently used primary end points for DMD clinical trials. A measurable distinction between dystrophic and control mice was seen at early time points in vivo compared with invasive muscle studies performed ex vivo. These assays shed light on normal and pathological responses to muscular exertion and have significant mechanistic and translational implications for the fields of basic myology and neuromuscular therapeutics.

Entities:  

Keywords:  Duchenne muscular dystrophy; open field; running wheel; whole limb force test

Mesh:

Year:  2016        PMID: 27932677      PMCID: PMC5401958          DOI: 10.1152/japplphysiol.00776.2016

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  41 in total

1.  Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy.

Authors:  Zejing Wang; James M Allen; Stanley R Riddell; Paul Gregorevic; Rainer Storb; Stephen J Tapscott; Jeffrey S Chamberlain; Christian S Kuhr
Journal:  Hum Gene Ther       Date:  2007-01       Impact factor: 5.695

2.  Beneficial effects of voluntary wheel running on the properties of dystrophic mouse muscle.

Authors:  A Hayes; D A Williams
Journal:  J Appl Physiol (1985)       Date:  1996-02

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

4.  Prevalence of fatigue, pain, and affective disorders in adults with duchenne muscular dystrophy and their associations with quality of life.

Authors:  Robert F Pangalila; Geertrudis A van den Bos; Bart Bartels; Michael Bergen; Henk J Stam; Marij E Roebroeck
Journal:  Arch Phys Med Rehabil       Date:  2015-02-27       Impact factor: 3.966

5.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

6.  Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles.

Authors:  J W Carnwath; D M Shotton
Journal:  J Neurol Sci       Date:  1987-08       Impact factor: 3.181

7.  A PCR-based assay for the wild-type dystrophin gene transferred into the mdx mouse.

Authors:  J B Shrager; A Naji; A M Kelly; H H Stedman
Journal:  Muscle Nerve       Date:  1992-10       Impact factor: 3.217

8.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy.

Authors:  J R Mendell; J T Kissel; A A Amato; W King; L Signore; T W Prior; Z Sahenk; S Benson; P E McAndrew; R Rice
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 9.  Clinical utility of serum biomarkers in Duchenne muscular dystrophy.

Authors:  Yetrib Hathout; Haeri Seol; Meng Hsuan J Han; Aiping Zhang; Kristy J Brown; Eric P Hoffman
Journal:  Clin Proteomics       Date:  2016-04-05       Impact factor: 3.988

10.  The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Julaine M Florence; Michelle Eagle; Eduard Gappmaier; Allan M Glanzman; Robert Spiegel; Jay Barth; Gary Elfring; Allen Reha; Stuart Peltz
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

View more
  2 in total

1.  A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy.

Authors:  Elizabeth M Gibbs; Rachelle H Crosbie-Watson
Journal:  J Vis Exp       Date:  2017-12-29       Impact factor: 1.355

2.  Social stress is lethal in the mdx model of Duchenne muscular dystrophy.

Authors:  Maria Razzoli; Angus Lindsay; Michelle L Law; Christopher M Chamberlain; William M Southern; Madeleine Berg; John Osborn; William C Engeland; Joseph M Metzger; James M Ervasti; Alessandro Bartolomucci
Journal:  EBioMedicine       Date:  2020-03-16       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.